{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:33:50Z","timestamp":1773012830905,"version":"3.50.1"},"reference-count":0,"publisher":"Journal of Infection in Developing Countries","issue":"09","license":[{"start":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T00:00:00Z","timestamp":1538265600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Infect Dev Ctries"],"abstract":"<jats:p>Introduction: Invasive fungal infection (IFI) is a major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. A previous history of IFI is not an absolute contraindication for allo-HSCT, particularly in the era of secondary antifungal prophylaxis (SAP). Prompt diagnosis and therapy are essential for HSCT outcome.\r\nMethodology: The charts of 58 allo-HSCT recipients [median age:29.5 (16-62); M\/F:41\/17] who had a previous history of IFI were retrospectively reviewed.\r\nResults: Possible IFI was demonstrated in 32 (55.2%), probable in 13 (22.4%) and proven in 13 patients (22.4%). All patients received SAP [liposomal amphoterisin B (n \ua78a 35), voriconazole (n \ua78a 17), caspofungin (n \ua78a 2), posaconazole (n \ua78a 1), combination therapy (n = 3)] which was started on the first day of the conditioning regimen. Treatment success was better in the voriconazole group when compared to the amphotericin B arm (100% vs 69.2%; p = 0.029). Development of breakthrough IFI was more frequent in patients on amphotericin B prophylaxis (42.4% vs 23.1%; p = 0.036). Clinical and radiological response were achieved in 13 of 18 patients (72.2%) who developed breakthrough infection. Overall survival of the study population was 13.5% at a median follow-up of 154 (7-3285) days. Fungal mortality was found to be 23%. Overall survival was better in the voriconazole arm, without statistical significance (90% vs 65.8%, p &gt; 0.05).\r\nConclusions: Secondary antifungal prophylaxis is considered to be an indispensible strategy in patients with pre-HSCT IFI history. Voriconazole seems to be a relatively better alternative despite an underlying necessity of larger prospective trials.<\/jats:p>","DOI":"10.3855\/jidc.9961","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T20:16:49Z","timestamp":1539289009000},"page":"799-805","source":"Crossref","is-referenced-by-count":6,"title":["Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection"],"prefix":"10.3855","volume":"12","author":[{"given":"Mehmet S","family":"Pepeler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eeyma","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep A","family":"Yegin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z\u00fcbeyde N","family":"\u00d6zkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zlem G","family":"Tun\u00e7can","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonca","family":"Erba\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurdan","family":"K\u00f6kt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fe","family":"Kalkanci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeki","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2222","published-online":{"date-parts":[[2018,9,30]]},"container-title":["The Journal of Infection in Developing Countries"],"original-title":[],"link":[{"URL":"https:\/\/jidc.org\/index.php\/journal\/article\/download\/9961\/1945","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jidc.org\/index.php\/journal\/article\/download\/9961\/1945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T04:22:38Z","timestamp":1560572558000},"score":1,"resource":{"primary":{"URL":"https:\/\/jidc.org\/index.php\/journal\/article\/view\/9961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,30]]},"references-count":0,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2018,10,11]]}},"URL":"https:\/\/doi.org\/10.3855\/jidc.9961","relation":{},"ISSN":["1972-2680"],"issn-type":[{"value":"1972-2680","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,30]]}}}